- Details
- Description
Strength:
Ponatinib equivalent to 45 mg
Composition:
Ponatinib Hydrochloride equivalent to Ponatinib 45 mg
Treatment:
Certain Philadelphia chromosome-positive leukemias, including CML and Ph+ ALL
Form:
Tablet*
Brand:
Ponaxen 45
Quantity Unit:
Tablets*
Manufacturer:
Everest Pharmaceuticals Ltd.
Ponaxen 45 is an oral targeted therapy containing ponatinib 45 mg, a tyrosine kinase inhibitor (TKI) that blocks abnormal BCR-ABL and other kinase activity. It is used for the treatment of certain Philadelphia chromosome-positive leukemias, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), under specialist medical supervision.
